Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer

Jo, Kwanhoon; Lim, Dong-Jun

doi:10.3904/kjim.2018.289

Cited by 33 publications

(36 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have indicated that TgAb and Tg are important biomarkers for the diagnosis of DTC ( 15 , 16 ). The diagnostic efficiency of exosomal miR-130a-3p was then compared with that of TgAb and Tg in patients with DTC and benign thyroid tumors.…”

Section: Resultsmentioning

confidence: 99%

Exosomal miR‑130a‑3p promotes the progression of differentiated thyroid cancer by targeting insulin‑like growth factor 1

et al. 2021

View full text Add to dashboard Cite

The aim of the present study was to determine the expression and diagnostic value of exosomal miR-130a-3p in the serum of patients with differentiated thyroid cancer (DTC). Exosomes were isolated from the serum of patients with DTC and were identified using transmission electron microscopy. A novel exosomal miRNA, miR-130a-3p, was found to be significantly decreased in the serum of patients with DTC compared with those with benign thyroid tumors and healthy controls. Further study revealed that exosomal miR-130a-3p was correlated with the malignant characteristics of DTC, including tumor diameter, lymph node metastasis (LNM) and higher TNM stage. Receiver operating characteristic curve analysis demonstrated that the area under the curve of exosomal miR-130a-3p was better compared with that of TgAb and Tg in patients with DTC. More importantly, the combined use of exosomal miR-130a-3p, TgAb and Tg significantly enhanced the sensitivity and specificity, indicating that exosomal miR-130a-3p is a sensitive biomarker for DTC. A dual luciferase reporter assay indicated that insulin-like growth factor (IGF)-1 was a target gene of miR-130a-3p. Pearson's correlation analysis revealed a negative correlation between serum IGF-1 and serum exosomal miR-130a-3p levels. More importantly, exosomes from patients with DTC increased the expression of IGF-1 and p-PI3K/p-AKT, but these effects were abolished by siRNA targeting IGF-1 in TPC-1 cells. Taken together, the findings of the present study indicated that reduced exosomal miR-130a-3p levels were associated with the risk of DTC and may be used as a biomarker for the diagnosis of DTC.

show abstract

Section: Resultsmentioning

confidence: 99%

Exosomal miR‑130a‑3p promotes the progression of differentiated thyroid cancer by targeting insulin‑like growth factor 1

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, there was no significant difference in the subjects who had anti-Tg earlier than the control group. This is expected, since anti-Tg is a well-established marker in differentiated thyroid cancer (DTC) diagnosis and is considered a less specific marker in thyroid disease compared to anti-TPO [23]. Even though our study was limited to 2 years, our results correlate with a study performed by Hutfless et al that showed the preexistence of anti-TPO and anti-Tg autoantibodies 7 years prior to the concise diagnosis of Hashimoto's (66% and 57% for anti-TPO and anti-Tg, respectively) and Graves' disease (57% and 47% for anti-TPO and anti-Tg, respectively) for 174 patients [24].…”

Section: Discussionmentioning

confidence: 99%

Significance of Anti-TPO as an Early Predictive Marker in Thyroid Disease

Siriwardhane

Krishna

Ranganathan

et al. 2019

Autoimmune Diseases

View full text Add to dashboard Cite

Even though most thyroid subjects are undiagnosed due to nonspecific symptoms, universal screening for thyroid disease is not recommended for the general population. In this study, our motive is to showcase the early appearance of thyroid autoantibody, anti-TPO, prior to the onset of thyroid hormone disruption; hence the addition of anti-TPO in conjunction with traditional thyroid markers TSH and FT4 would aid to reduce the long-term morbidity and associated health concerns. Here, a total of 4581 subjects were tested multiple times for TSH, FT4, anti-TPO, and anti-Tg and followed up for 2 years. We streamlined our subjects into two groups, A1 (euthyroid at first visit, but converted to subclinical/overt hypothyroidism in follow-up visits) and A2 (euthyroid at first visit, but converted to hyperthyroidism in follow-up visits). According to our results, 73% of hypothyroid subjects (from group A1) and 68.6% of hyperthyroid subjects (from group A2) had anti-TPO 252 (±33) and 277 (±151) days prior to the onset of the thyroid dysfunction, respectively. Both subclinical/overt hypothyroidism and hyperthyroidism showed a significantly higher percentage of subjects who had anti-TPO prior to the onset of thyroid dysfunction compared to the combined control group. However, there was no significant difference in the subjects who had anti-Tg earlier than the control group. Further assessment showed that only anti-TPO could be used as a standalone marker but not anti-Tg. Our results showcase that anti-TPO appear prior to the onset of thyroid hormone dysfunction; hence testing anti-TPO in conjunction with TSH would greatly aid to identify potentially risk individuals and prevent long-term morbidity.

show abstract

“…• THW: This consists of L-T4 deprivation for 3 to 4 wk or triiodothyronine (T3) treatment for 4 wk with subsequent T3 discontinuation for 2 wk before RAI scintigraphy. • rhTSH stimulation: This consists of administration of rhTSH given as 2 intramuscular injections of 0.9 mg on each of 2 consecutive days with RAI or 18 F-FDG given the next day. rhTSH may be required if the patient cannot be prepared by near-total thyroidectomy, in patients with significant comorbidities in whom prolonged hypothyroidism would represent a risk or cannot be tolerated, in patients with pituitary insufficiency, or in those with isolated TSH deficiency.…”

Section: B Patient Preparationmentioning

confidence: 99%

“…The typical administered dosage for oncology is 370-740 MBq (10-20 mCi). 18 F-FDG may be used to identify tumors that are not detected with RAI. These are usually less well-differentiated tumors ( 18 F-FDG-positive, radioiodine-negative) and are less likely to respond to 131 I-NaI treatment.…”

Section: Radiopharmaceuticals and Dosagementioning

confidence: 99%